|
|
 |
|
Viewing report
|
|
|
|
Gambro Medical Device Company Intelligence Report
Espicom Business Intelligence Ltd, Nov 2010, Pages: 22
Gambro AB develops, manufactures and supplies products and therapies for kidney and liver dialysis, myeloma kidney therapy and other extracorporeal therapies for chronic and acute patients.
The company’s portfolio of products comprises:Haemodialysis (HD) products - dialysis monitors, dialysers, concentrators, ultrafilters and blood lines; Peritoneal dialysis (PD) products - such as cyclers, catheters and prescription and information management software. In August 2010, Gambro decided to exit the PD business and agreed to sell these products and related assets to Fresenius. The transaction is expected to be completed by the end of 2010; Continuous renal replacement therapy (CRRT) products – monitors, haemofilter sets, plasmafiltration sets; catheters, blood warmers and fluids; Vascular access products – short- and long-term catheters and fistula needles; and Water purification systems. In October 2010, Gambro reached an agreement to sell its US medical water business to Mar Cor Purification.
In January 2010, Gambro acquired CHF Solutions, a producer of medical devices for cardiac care, which has enabled the company to accelerate the adoption of ultrafiltration for fluid overload.
Gambro was founded in 1964 and has more than 8,000 employees, production facilities in nine countries, sales subsidiaries in more than 40 countries and sales in more than 100 countries.
Sweden's Wallenberg family controls Gambro through its Investor AB investment firm. In June 2006, the family took over Gambro in a transaction valued at US$5.4 billion. The Wallenbergs previously owned 19.9% of the company before they made the purchase with EQT Partners, a Stockholm-based buyout firm partly-owned by Investor. As of September 2010, EQT Partners owned 51% of Gambro and Investor held the remaining 49% (Investor also owns 10% of Gambro through its investment in EQT).
In December 2004, Gambro sold its US healthcare clinics to rival DaVita for US$3.1 billion. In November 2006, Gambro's businesses were split into three independent businesses – Gambro Renal Products, to make products for dialysis machines and provide blood purification for hospital intensive care units; Gambro BCT, to sell blood collection and separation equipment; and Gambro Healthcare, to operate healthcare facilities in Europe, South America, Asia and Australia.
Gambro Renal Products subsequently became the new Gambro AB, while Gambro BCT changed its name to Caridian BCT. In May 2007, Gambro Healthcare was sold to Bridgepoint, a European private equity firm, and is now known as Diaverum. Within the healthcare industry, Investor also owns Möelnlycke Health Care, a provider of single-use surgical and wound care products and services, and Aleris, a Scandinavian healthcare and care service provider. EQT owns Dako Denmark, which undertakes medical tests used to diagnose cancer.
This company report provides
Overview
- Key contact information
- Introduction to the company and its current activities
- Summary of its financial performance
- Who are the company’s major competitors?
- Key recent events in an “at a glance” format
Financial Review
- Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
- Table providing in-depth five-year financial analysis
- Employee data, including breakdown by company division and geographic location
Strategic Focus
- Investigates the company’s aims and its areas of focus
Products
- Core product areas, key brands, product approvals and launches
Research and Development
- How much has been invested in R&D?
- Where is the research based?
- What alliances and agreements does the company have and with whom?
Manufacturing and Distribution
- Identifying the company’s manufacturing locations
- Sales and marketing facilities
Agreements
- With whom has the company reached agreements and what do they involve?
- Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Litigation
Key Corporate Events
|
|
|
|
